K Number

Device Name

MUMPS IGG ELISA TESTY

Manufacturer

GULL LABORATORIES, INC.

Date Cleared

1997-11-04

(168 days)

Product Code

LJY

Regulation Number

866.3380

Intended Use

The MUMPS IgG ELISA TEST is to be used in the testing of human serum specimens from asymptomatic and symptomatic children and adults for whom quantitation of the presence or the qualitative presence or absence of detectable IgG antibody to mumps virus is warranted in the determination of immunological experience pertaining to infection with mumps virus and as an aid in the diagnosis of mumps infection.

Device Description

The Mumps IgG ELISA Test is an in vitro diagnostic medical device intended for the qualitative and semi-quantitative detection of IgG antibody to the mumps virus in human serum by the enzyme-linked immunosorbent assay (ELISA) method. The Mumps IgG ELISA Test is comprised of the following items: Mumps Antigen-Coated ELISA Plate; IgG Specimen Diluent; Conjugate; Substrate Buffer; p-NPP Tablets; Stopping Reagent; Calibrator 1 and 2; Positive Control and Negative Control; Reference Serum; 20X Wash Solution; ELISA Plate Sealer; Resealable Storage Bag; ELISA Worksheet; Activity Units Graph Paper. When the Mumps IgG ELISA Test is employed, diluted patient serum is incubated with purified mumps virus antigen bound to the ELISA plate wells. If antibodies to the mumps virus are present, they bind to the antigen and do not rinse off. Subsequently when enzyme-labeled antihuman IgG is added to the reaction site it binds to the immobilized IgG antibodies. After washing and the addition of a chromogenic substrate and stopping reagent, specimens containing antibodies to the mumps virus produce a color endpoint reaction which can be read with a standard ELISA plate reader.

More Information

Contact

Type

Center

Panel

Date Received

Product Code

Subsequent Product Codes

Applicant Name (Manufacturer)

Device Name

Decision

Street 1

Street 2

City

State

Country Code

ZIP

Postal Code

Class Advise Committee

SSP Indicator

Third Party Reviewed

Expedited Review

Predicate Devices

K971857

Reference Devices

Mumps Stat Test Kit

AI/ML (Artificial Intelligence / Machine Learning)

No
The device description details a standard ELISA assay, and there are no mentions of AI, ML, or related concepts in the summary.

Therapeutic

No.
Explanation: The device is an in vitro diagnostic (IVD) medical device used to detect antibodies for diagnostic purposes, not to treat or cure a disease.

Diagnostic

Yes

The "Intended Use / Indications for Use" states that the device is "as an aid in the diagnosis of mumps infection." Additionally, the "Device Description" section explicitly calls it "an in vitro diagnostic medical device."

SaMD (Software as a Medical Device)

The device description explicitly lists multiple physical components (ELISA plate, reagents, controls, etc.) that are essential for the device's function, indicating it is a hardware-based in vitro diagnostic test kit, not software only.

IVD (In Vitro Diagnostic)

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

Intended Use: The intended use explicitly states it is for "testing of human serum specimens" and is used "in the determination of immunological experience pertaining to infection with mumps virus and as an aid in the diagnosis of mumps infection." This clearly indicates a diagnostic purpose using biological samples.
Device Description: The description states it is an "in vitro diagnostic medical device intended for the qualitative and semi-quantitative detection of IgG antibody to the mumps virus in human serum by the enzyme-linked immunosorbent assay (ELISA) method." This directly identifies it as an in vitro diagnostic device.
Method: The device uses the ELISA method, which is a common laboratory technique for detecting and quantifying substances in biological samples.
Components: The components listed are typical of an ELISA kit used for diagnostic testing in a laboratory setting.
Performance Studies: The performance studies describe testing human blood samples and comparing the results to a predicate device, which is standard practice for evaluating the performance of IVDs.

All of these factors align with the definition and characteristics of an In Vitro Diagnostic device.

PCCP (Predetermined Change Control Plan) Authorized

N/A

Overview

Intended Use / Indications for Use

The Mumps IgG ELISA Test is intended for the qualitative and semi-quantitative detection of IgG antibody to the mumps virus in human serum by the enzymelinked immunosorbent assay (ELISA) method. When performed according to instructions, the Mumps IgG ELISA Test is of value in the determination of immunological experience pertaining to infection with mumps virus and in the diagnosis of mumps virus associated disease.
The MUMPS IgG ELISA TEST is to be used in the testing of human serum specimens from asymptomatic and symptomatic children and adults for whom quantitation of the presence or the qualitative presence or absence of detectable IgG antibody to mumps virus is warranted in the determination of immunological experience pertaining to infection with mumps virus and as an aid in the diagnosis of mumps infection.

Product codes

LJY

Device Description

Mumps Antigen-Coated ELISA Plate: One 96-well plate comprised of 1. twelve 8-well strips with breakaway wells, each well coated with partially purified mumps antigen (Enders Strain).
IgG Specimen Diluent: One bottle containing 30 ml of a lavender colored 2. dilution buffer with sodium azide.
Conjugate: One bottle containing 15 ml of a pink colored solution of alkaline 3. phosphatase-labeled antihuman IgG (Caprine) with sodium azide.
Substrate Buffer: One bottle containing 30 ml of a blue colored buffer 4. solution with sodium azide.
p-NPP Tablets: One foil pack containing 6 tablets of p-nitrophenyl ~. phosphate (p-NPP).
Stopping Reagent: One bottle containing 30 ml of a colorless solution of 6. 1.5 N sodium hydroxide (NaOH).
Calibrator 1 and 2: One vial of each containing 200 ul of serum (human) 7. with sodium azide.
Positive Control and Negative Control: One vial of each containing 200 µl 8. of serum (human) with sodium azide.
Reference Serum: One vial containing 400 µl of serum (human) with 9. sodium azide.
20X Wash Solution: One bottle containing 60 ml of a green colored solution 10. with detergent and sodium azide.
ELISA Plate Sealer: One acetate sheet with contact adhesive. 11.
Resealable Storage Bag: One plastic sealable bag. 12.
1. ELISA Worksheet: One work sheet for recording data.
Activity Units Graph Paper: One sheet of graph paper for activity unit 14. computations.
When the Mumps IgG ELISA Test is employed, diluted patient serum is incubated with purified mumps virus antigen bound to the ELISA plate wells. If antibodies to the mumps virus are present, they bind to the antigen and do not rinse off. Subsequently when enzyme-labeled antihuman IgG is added to the reaction site it binds to the immobilized IgG antibodies. After washing and the addition of a chromogenic substrate and stopping reagent, specimens containing antibodies to the mumps virus produce a color endpoint reaction which can be read with a standard ELISA plate reader.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

children and adults

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Blood samples from 144 donors at a regional blood bank were evaluated for the presence of IgG antibody to mumps virus at Gull Laboratories, Inc. with the Mumps IgG ELISA Test and the Mumps Stat Test Kit. Discordant samples were retested using the same two tests. Without incorporating the results of retesting the discordant samples, the agreement between the two test systems was 97.9% (139/142). The relative sensitivity and relative specificity of the Mumps IgG ELISA Test were 97.5% (119/122) with a 95% confidence interval of 93.0% - 99.5% and 100% (20/20) with a 95% confidence interval of 83.2% - 100% when compared to the Mumps Stat Test Kit. Two equivocal samples were not included in the calculations which were based on a 95% confidence interval as determined by the Exact Method.

Clinical specimens from 123 patients were tested for IgG antibodies to mumps virus using the Mumps IgG ELISA Test and the Mumps Stat Test Kit in a hospital in the Northeastern region of the United States. Discordant samples were retested using the same two tests. Without incorporating the results of retesting the discordant samples, the agreement between the two test systems was 96.6% (114/117). The relative sensitivity and relative specificity of the Mumps IgG ELISA Test were 98.0 (96/98) with a 95% confidence interval of 92.8% - 99.8% and 94.7% (18/19) with a 95% confidence interval of 74.0% - 99.9% respectively when compared with the Mumps Stat Test Kit. Six equivocal samples were not included in the calculations which were based on a 95% confidence interval as determined by the Exact Method.

Clinical specimens from 123 patients were tested for IgG antibodies to mumps virus using the Mumps IgG ELISA Test and the Mumps Stat Test Kit in a hospital in the Southwestern region of the United States. Discordant samples were retested on the same two tests. Without incorporating the results of retesting the discordant samples, the agreement between the two test systems was 93.2% (109/117). The relative sensitivity and relative specificity of the Mumps IgG ELISA Test were 94.3% (99/110) with a 95% confidence interval of 88.0% - 97.9% and 83.3% (10/13) with a 95% confidence interval of 51.6% - 97.9% respectively when compared with the Mumps Stat Test Kit. Six equivocal samples were not included in the calculations which were based on a 95% confidence interval as determined by the Exact Method.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Agreement: 97.9% (139/142)
Relative sensitivity: 97.5% (119/122) with a 95% confidence interval of 93.0% - 99.5%
Relative specificity: 100% (20/20) with a 95% confidence interval of 83.2% - 100%

Agreement: 96.6% (114/117)
Relative sensitivity: 98.0 (96/98) with a 95% confidence interval of 92.8% - 99.8%
Relative specificity: 94.7% (18/19) with a 95% confidence interval of 74.0% - 99.9%

Agreement: 93.2% (109/117)
Relative sensitivity: 94.3% (99/110) with a 95% confidence interval of 88.0% - 97.9%
Relative specificity: 83.3% (10/13) with a 95% confidence interval of 51.6% - 97.9%

Predicate Device(s)

K971857 Mumps Stat Test Kit

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

Regulation Number and Section

§ 866.3380 Mumps virus serological reagents.

(a)
Identification. Mumps virus serological reagents consist of antigens and antisera used in serological tests to identify antibodies to mumps virus in serum. Additionally, some of these reagents consist of antisera conjugated with a fluorescent dye (immunofluorescent reagents) used in serological tests to identify mumps viruses from tissue culture isolates derived from clinical specimens. The identification aids in the diagnosis of mumps and provides epidemiological information on mumps. Mumps is an acute contagious disease, particularly in children, characterized by an enlargement of one or both of the parotid glands (glands situated near the ear), although other organs may also be involved.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.

Summary

NOV - 4 1997

EXHIBIT G - REVISED 07/31/97

510(k) SUMMARY FOR MUMPS IgG ELISA TEST

SUBMITTER:

Gull Laboratories, Inc. 1011 Murray Holladay Road Salt Lake City, UT 84117 (801) 263-3524

CONTACT PERSON:

Fred W. Rachford

DATE:

April 30, 1997

DEVICE NAME:

Trade/Proprietary Name:	Mumps IgG ELISA Test
Common/Usual Name:	Anti-Mumps IgG Antibody Test
Classification Name:	Mumps Virus Serological Reagent

PREDICATE DEVICE: Mumps Stat Test Kit / BioWhittaker, Inc.

DEVICE DESCRIPTION:

The Mumps IgG ELISA Test is comprised of the following items:

Mumps Antigen-Coated ELISA Plate: One 96-well plate comprised of 1 . twelve 8-well strips with breakaway wells, each well coated with partially purified mumps antigen (Enders Strain).

IgG Specimen Diluent: One bottle containing 30 ml of a lavender colored 2. dilution buffer with sodium azide.
Conjugate: One bottle containing 15 ml of a pink colored solution of alkaline 3. phosphatase-labeled antihuman IgG (Caprine) with sodium azide.
Substrate Buffer: One bottle containing 30 ml of a blue colored buffer 4. solution with sodium azide.
p-NPP Tablets: One foil pack containing 6 tablets of p-nitrophenyl న్. phosphate (p-NPP).
Stopping Reagent: One bottle containing 30 ml of a colorless solution of 6. 1.5 N sodium hydroxide (NaOH).
Calibrator 1 and 2: One vial of each containing 200 ul of serum (human) 7. with sodium azide.
Positive Control and Negative Control: One vial of each containing 200 µl 8. of serum (human) with sodium azide.
Reference Serum: One vial containing 400 µl of serum (human) with 9. sodium azide.
20X Wash Solution: One bottle containing 60 ml of a green colored solution 10. with detergent and sodium azide.
ELISA Plate Sealer: One acetate sheet with contact adhesive. 11.
Resealable Storage Bag: One plastic sealable bag. 12.
1. ELISA Worksheet: One work sheet for recording data.
Activity Units Graph Paper: One sheet of graph paper for activity unit 14. computations.

When the Mumps IgG ELISA Test is employed, diluted patient serum is incubated with purified mumps virus antigen bound to the ELISA plate wells. If antibodies to the mumps virus are present, they bind to the antigen and do not rinse off. Subsequently when enzyme-labeled antihuman IgG is added to the reaction site it binds to the immobilized IgG antibodies. After washing and the addition of a chromogenic substrate and stopping reagent, specimens containing antibodies to the mumps virus produce a color endpoint reaction which can be read with a standard ELISA plate reader.

INTENDED USE:

immunological experience pertaining to infection with mumps virus and in the diagnosis of mumps virus associated disease.

TECHNOLOGICAL COMPARISON TO PREDICATE DEVICE:

The Mumps IgG ELISA Test and the Mumps Stat Test Kit both are technologically based on the enzyme-linked immunosorbent assay (ELISA) method.

SUBSTANTIAL EQUIVALENCE PERFORMANCE DATA:

CONCLUSIONS:

The Mumps IgG ELISA Test is believed to be substantially equivalent to the Mumps Stat Test Kit. This assessment is based on (1) the two tests are technologically equivalent, both being based on the enzyme-linked immunosorbent

assay methods, (2) the intended use of each test is comparable with only slight differences in the wording, and (3) the data from clinical studies conducted at Gull Laboratories, Inc. and two outside clinical institutions in most instances demonstrated that the agreement between the two test systems and the relative sensitivity and relative specificity when comparing the two test systems.

Image /page/4/Picture/2 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the bird symbol. The text is in all capital letters and is evenly spaced around the circle.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

NOV - 4 1997

· Fred W. Rachford, Ph.D. Senior Vice President Gull Laboratories, Inc. 1011 East 4800 South Salt Lake City, Utah 84117

Re: K971857

Trade Name: Mumps IgG ELISA Test Regulatory Class: I Product Code: LJY Dated: August 18, 1997 Received: August 19, 1997

Dear Dr. Rachford:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations.

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Autman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

EXHIBIT F - REVISED 10/02/97

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________

Device Name: _________________________________________________________________________________________________________________________________________________________________

Product Number:

Indications For Use:

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Dan Cooper

(Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number_K 971857